Literature DB >> 7894054

Automated fluorescent genomic sequencing as applied to the methylation analysis of the human ornithine decarboxylase gene.

S Myöhänen1, J Wahlfors, J Jänne.   

Abstract

A genomic sequencing method for an automated DNA sequencer was developed. The method described here is an improved version of the previously published protocol, which utilizes bisulfite-induced modification of genomic DNA. In our method, the modified DNA is purified without a time-consuming dialysis, and the subsequent 2-step DNA amplification is carried out with one biotinylated primer in order to separate and isolate the strands of the product with the aid of streptavidin-coated magnetic beads. The strands are then sequenced with fluorescent primers and automated DNA sequencer. This provides means to determine reliably the methylation status of cytosines as well as the degree of methylation in a given CpG, site of the target sequence. The method was successfully applied to analyze the promoter region and the 11th exon of the human ornithine decarboxylase ODC gene in various human myeloma cell lines. The study revealed a totally unmethylated promoter region in every cell line studied, whereas the protein coding region appeared to be extensively methylated, although a dexamethasone resistant cell line displayed demethylation in certain CpG sequences. Also, a previously unknown ODC allele was detected.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7894054     DOI: 10.3109/10425179409039698

Source DB:  PubMed          Journal:  DNA Seq        ISSN: 1026-7913


  8 in total

1.  Protein-DNA binding and CpG methylation at nucleotide resolution of latency-associated promoters Qp, Cp, and LMP1p of Epstein-Barr virus.

Authors:  D Salamon; M Takacs; D Ujvari; J Uhlig; H Wolf; J Minarovits; H H Niller
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

2.  High-resolution analysis of CpG methylation and in vivo protein-DNA interactions at the alternative Epstein-Barr virus latency promoters Qp and Cp in the nasopharyngeal carcinoma cell line C666-1.

Authors:  Agnes Bakos; Ferenc Banati; Anita Koroknai; Maria Takacs; Daniel Salamon; Susanna Minarovits-Kormuta; Fritz Schwarzmann; Hans Wolf; Hans Helmut Niller; Janos Minarovits
Journal:  Virus Genes       Date:  2007-05-18       Impact factor: 2.332

Review 3.  Identifying 5-methylcytosine and related modifications in DNA genomes.

Authors:  T Rein; M L DePamphilis; H Zorbas
Journal:  Nucleic Acids Res       Date:  1998-05-15       Impact factor: 16.971

4.  High-resolution methylation analysis and in vivo protein-DNA binding at the promoter of the viral oncogene LMP2A in B cell lines carrying latent Epstein-Barr virus genomes.

Authors:  Daniel Salamon; Maria Takacs; Fritz Schwarzmann; Hans Wolf; Janos Minarovits; Hans Helmut Niller
Journal:  Virus Genes       Date:  2003-08       Impact factor: 2.332

5.  Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands.

Authors:  J G Herman; J R Graff; S Myöhänen; B D Nelkin; S B Baylin
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-03       Impact factor: 11.205

6.  Hypermethylation of the 5' CpG island of the p14ARF flanking exon 1β in human colorectal cancer displaying a restricted pattern of p53 overexpression concomitant with increased MDM2 expression.

Authors:  Christine Nyiraneza; Christine Sempoux; Roger Detry; Alex Kartheuser; Karin Dahan
Journal:  Clin Epigenetics       Date:  2012-06-15       Impact factor: 6.551

7.  An improved sequencing-based strategy to estimate locus-specific DNA methylation.

Authors:  Giulia Brisotto; Alessandra di Gennaro; Valentina Damiano; Michela Armellin; Tiziana Perin; Roberta Maestro; Manuela Santarosa
Journal:  BMC Cancer       Date:  2015-09-21       Impact factor: 4.430

8.  Hypermethylation of the WT1 and calcitonin gene promoter regions at chromosome 11p in human colorectal cancer.

Authors:  M O Hiltunen; J Koistinaho; L Alhonen; S Myöhänen; S Marin; V M Kosma; M Pääkkönen; J Jänne
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.